COLLABORATION, LICENSE AND OPTION AGREEMENTLicense and Option Agreement • March 19th, 2020 • Curis Inc • Biological products, (no disgnostic substances)
This Second Amendment to Collaboration, License and Option Agreement (this “Second Amendment”) is entered into as of February 5, 2020 (the “Second Amendment Date”), by and between Aurigene Discovery Technologies Limited, a company organized under the laws of India, having an address of 39-40, KIADB Industrial Area, Phase II, Electronic City Hosur Road, Bangalore - 560100 Karnataka, India (“Aurigene”), and Curis, Inc., a corporation organized under the laws of Delaware, USA, having an address of 4 Maguire Road, Lexington, Massachusetts 02421-3112, USA (“Curis”).
OPTION AND LICENSE AGREEMENTOption and License Agreement • March 19th, 2020 • Curis Inc • Biological products, (no disgnostic substances) • New York
This Option and License Agreement (together with any exhibits or schedules attached hereto, this “Agreement”) is made and entered into as of January 6, 2020 (the “Effective Date”), by and between ImmuNext, Inc., a Delaware corporation located at 1 Medical Center Drive, HB7937, Lebanon, New Hampshire 03755 (“ImmuNext”), and Curis, Inc., a Delaware corporation, with offices at 4 Maguire Road, Lexington, Massachusetts 02421 (“Curis”). ImmuNext and Curis are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
